SOURCE: Barrier Therapeutics, Inc.

May 31, 2005 10:00 ET

Barrier Therapeutics to Present at Pacific Growth Equities 2005 Life Sciences Growth Conference

PRINCETON, NJ -- (MARKET WIRE) -- May 31, 2005 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced that Dr. Geert Cauwenbergh, Chairman and Chief Executive Officer of Barrier Therapeutics, is scheduled to provide an update to the investment community on Barrier's marketed product and clinical-stage product pipeline at the Pacific Growth Equities 2005 Life Sciences Growth Conference. The conference is being held from June 6-8, 2005 at the Mark Hopkins InterContinental Hotel in San Francisco. Dr. Cauwenbergh is scheduled to present on Tuesday, June 7th at 8:30 am, Pacific Time.

Dr. Cauwenbergh's presentation will also be available live via a webcast that can be accessed through the Company's website: www.barriertherapeutics.com.

About Barrier Therapeutics, Inc.

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of pharmaceutical products in the field of dermatology. The Company currently markets Solagé® (mequinol 2%, tretinoin 0.01%) Topical Solution in the U.S. and Canada for the treatment of solar lentigines, a common condition also known as "age spots" or "liver spots," and for the broader indication including related hyperpigmented lesions in Canada. Barrier has eight product candidates in various stages of clinical development. The four most advanced product candidates include one for the treatment of diaper dermatitis complicated by candidiasis, which is in registration, and three products, which are in or entering Phase 3 clinical trials for the treatment of seborrheic dermatitis, fungal infections, including vaginal candidiasis and onychomycosis, and congenital ichthyosis. Barrier has product candidates in earlier stages of clinical development for the treatment of acne, psoriasis and fungal infections. The Company is headquartered in Princeton, New Jersey, and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada. Web site: http://www.barriertherapeutics.com.

Contact Information

  • Contact:
    Barrier Therapeutics, Inc.
    Anne M. VanLent
    609-945-1202

    Noonan Russo
    Emily Poe
    212-845-4266